Localized Prostate Cancer VL

Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm Phase 2 Trial - Eugene Shenderov

Details
In a conversation with Andrea Miyahira, Eugene Shenderov discusses the recent study conducted by his team and published under the title, “Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm, Phase II Trial.” In the past, immunotherapies have demonstrated limited efficacy in prostate cancer treatment. This is primarily due to the necessity for selective immunotherapy in this settin...

Journal of Urology Open Plus - Revolutionizing Access and Innovation in Urology Research - John W. Davis

Details
John Davis, Professor of Urology, discusses the new Journal of Urology Open Plus with Phillip Koo. The journal aims to provide fully gold open access, making research freely accessible to all. It addresses the need for easily accessible research, especially for publicly funded projects. The concept of cascading allows submissions to be considered across multiple journals within the AUA. The focus...

Improving Primary Prostate Cancer Diagnosis Through Risk Stratified Screening: a European Perspective - Sigrid Carlsson

Details
Matt Cooperberg interviews Sigrid Carlsson, Director of Research at MSK for Urology, on the evolution of prostate cancer screening policy and ongoing innovative trials. Carlsson, an integral member of the AUA's screening guideline panel, highlights the transition from the traditional DRE and PSA tests to a new era of risk-stratified screening, aiming to optimize the benefits of PSA testing while m...

Advancements in Prostate Cancer Screening: Inclusion of At-Risk Groups, Imaging & Biomarkers - An AUA Guidelines Update - Daniel Lin

Details
Matthew Cooperberg and Daniel Lin discuss the update to the American Urological Association's (AUA) prostate cancer screening guideline in this discussion. They highlight the collaborative effort involved in the guideline update, involving a large group of experts and reviewers. They compare the AUA's process with that of the National Comprehensive Cancer Network (NCCN) and discuss the systematic...

Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu

Details
Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...

15-Year Follow-Up of the ProtecT Trial: Discussing Results and Changes in Prostate Cancer Management, The ProtecT Trial - Oliver Sartor

Details
Alicia Morgans and Oliver Sartor discuss the New England Journal of Medicine editorial on the fifteen-year follow-up of the ProtecT trial. The ProtecT trial was a UK-based study where 1600 men were randomized to either active monitoring, prostatectomy, or radiotherapy. The trial followed up on these men for 15 years and found that there were no significant differences in mortality between the grou...

ProtecT Trial Reveals New Insights for Prostate Cancer Treatment: Implications for Low-Risk vs. High-Risk Patients - David Penson

Details
In this conversation, Alicia Morgans speaks with Professor David Penson about the ProtecT trial and its implications for clinical practice. The study found no difference in outcomes between surgery, radiation, and conservative management in prostate cancer patients after 10 years of follow-up. However, a recent 15-year follow-up has revealed some new findings. The cohort of patients enrolled in th...

Advancing Rectal Spacing in Prostate Cancer Radiation Therapy: The Benefits of Barrigel® - Neil Mariados

Details
Zachary Klaassen is joined by Neil Mariados, the lead author on both the SpaceOAR™ and Barrigel® trials to discuss rectal spacing, which is used in radiation therapy to reduce rectal toxicity in prostate cancer patients. Rectal spacing involves inserting a gel between the rectum and the prostate to create a space that reduces the dose to the rectum during radiation. They compare the two FDA-approv...

Improving MRI for Localized Prostate Cancer Diagnosis: The Need for a Standardized and Quantitative MRI Approach - Tyler Seibert

Details
Matt Cooperberg interviews Tyler Seibert, a radiation oncologist and assistant professor at UC San Diego. They focus on the use of MRI for localized prostate cancer, which has drastically changed the diagnostic pathway for prostate cancer in the last decade. However, the variability in the way the MRI is conducted is a problem. Each imaging center sets up its own protocol, and this lack of coordin...

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases - Beyond the Abstract

Details
The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] > 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatectomy following adjuvant apalutamide and androgen-deprivation therapy. In this substudy, relugolix, an oral gonadotropin-releasing hormone antagonist,...